MitoRx

MitoRx Therapeutics is a biotechnology company focused on developing first-in-class mitochondrial protective therapeutics to treat degenerative diseases. The company's platform utilizes a novel hydrogen sulfide donor technology to restore mitochondrial function and prevent cell death. Their lead programs target Duchenne muscular dystrophy and Huntington's disease, where mitochondrial dysfunction is a key driver of pathology. MitoRx is also exploring applications in respiratory diseases such as COPD and IPF. By addressing the root cause of mitochondrial decay, the company aims to provide disease-modifying treatments for conditions with high unmet medical needs.